Trial Profile

A Phase I dose escalating trial evaluating the safety and efficacy of RAD 402 in patients with advanced prostate cancer

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 21 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Jul 2025 According to a Radiopharm Theranostics media release, Radiopharm and Cyclotek entered a supply agreement in which Cyclotek will produce and provide doses of 161Tb-RAD 402 to support Radiopharms upcoming Phase 1 clinical trial in prostate cancer in Australia.
29 Jul 2025 According to a Radiopharm Theranostics media release, company plans to submit a package for ethics approval to begin a Phase 1 clinical trial in prostate cancer for 161Tb-RAD 402 and expects to begin dosing subjects in this clinical trial in the fourth quarter of 2025 in Australia.
24 Jun 2025 According to a Radiopharm Theranostics media release, ethics approval and Phase 1 clinical trial start in prostate cancer anticipated in 2H 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com